Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor Publication Model-informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor CertaraFebruary 15, 2018
Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies Publication Exposure-response of Veliparib to Inform Phase 2 Trial Design in Refractory or Relapsed Patients with Hematological Malignancies CertaraNovember 1, 2017
Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach Publication Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach CertaraSeptember 15, 2017
Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types Publication Parent‐metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT‐888), a PARP Inhibitor, in Patients with BRCA 1/2–mutated Cancer or PARP‐sensitive Tumor Types CertaraAugust 1, 2017
Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients Publication Response Analysis of Alvocidib (Flavopiridol) Treatment by Bolus or Hybrid Administration in Newly Diagnosed or Relapsed/Refractory Acute Leukemia Patients CertaraJuly 15, 2017
Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response Publication Time Dependent Pharmacokinetics of Pembrolizumab in Patients with Solid Tumor and Its Correlation with Best Overall Response CertaraJune 1, 2017
Evaluation of Dosing Strategy for Pembrolizumab for Oncology Indications Publication Evaluation of Dosing Strategy for Pembrolizumab for Oncology Indications CertaraMay 1, 2017
CYP2C9 Genotype-dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites Publication CYP2C9 Genotype-dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites CertaraMarch 1, 2017
Population Pharmacokinetics and Exposure-response of Osimertinib in Patients with Non-small Cell Lung Cancer Publication Population Pharmacokinetics and Exposure-response of Osimertinib in Patients with Non-small Cell Lung Cancer CertaraDecember 18, 2016
Profiling the Relationship Between Tumor-associated Macrophages and Pharmacokinetics of Liposomal Agents in Preclinical Murine Models Publication Profiling the Relationship Between Tumor-associated Macrophages and Pharmacokinetics of Liposomal Agents in Preclinical Murine Models CertaraOctober 5, 2016
